|
|
|
|
BAY 43-9006
A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called raf kinase inhibitors. (National Cancer Institute)
Bayer and Onyx Announce Initiation of Phase III Clinical Trial of ... Mar 8, 2005
...(Nasdaq: ONXX) today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial of BAY 43-9006 administered as a ... PR Newswire (press release)
Bayer and Onyx Announce Initiation of Phase III Clinical Trial of ... Mar 8, 2005
...today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial of BAY 43-9006 administered as a single agent in ... mysan.de (Pressemitteilung),
Bayer and Onyx begin phase III liver cancer trial Mar 9, 2005
Bayer Pharmaceuticals and Onyx Pharmaceuticals have initiated a phase III clinical trial of BAY 43-9006 as a single agent in patients with advanced liver cancer ... Pharmaceutical Business Review
A Novel RAF kinase and VEGFR Inhibitor as Single Agent Therapy for ... Mar 8, 2005
Pharmaceuticals, Inc.today announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial of BAY 43-9006 administered as a ... RxPG NEWS,
Onyx Pharmaceuticals Reports Fourth Quarter and Year-End 2004 ... Mar 3, 2005
The net loss for the fourth quarter of 2004 reflects the continued, and growing, investment in BAY 43-9006, an anticancer compound that Onyx is codeveloping ... ArriveNet (press release),
Bayer Heals Itself Mar 3, 2005
The company is currently working with Onyx Pharmaceuticals (Nasdaq: ONXX) to develop BAY-43-9006, a medicine currently in phase 3 development for renal cancer. ... Motley Fool
Onyx Pharmaceuticals Names Thomas G. Wiggans to Its Board Mar 10, 2005
With its collaborators, the company is developing small molecule drugs, including BAY 43-9006 with Bayer Pharmaceuticals Corporation. ... PR Newswire (press release)
BAYER: Bayer and Onyx Announce Initiation of Phase III Clinical ... Mar 11, 2005
SUMMARY: Bayer and Onyx also reported that the US Food and Drug Administration (FDA) has completed a Special Protocol Assessment (SPA) for the Phase III HCC ... Webbolt Business News (subscription),
Onyx Pharmaceuticals posts wider 4Q loss Mar 3, 2005
The company attributed the quarterly loss to growing investment in BAY 43-9006, an experimental drug aimed at treating various kinds of cancer by blocking ... BusinessWeek
Biz Buzz: Dreyer's posts loss again Mar 8, 2005
...(ONXX) said it began a Phase III clinical trial of Bay 43-9006, a cancer treatment the firm is working on in conjunction with Bayer Pharmaceuticals Corp. ... Contra Costa Times,
Onyx, Bayer start Phase III cancer drug trial Mar 8, 2005
...and Bayer Pharmaceuticals Corp. said Tuesday that they have started a Phase III clinical trial of the drug BAY 43-9006 for the treatment of liver cancer. ... East Bay Business Times,
Archives: The following articles may no longer be available on the web. If you want to inquire on a particular article, please contact the source publication (listed in parentheses).
Encouraging Data on BAY 43-9006 in Combination With Standard ... Jun 6, 2004
...(Nasdaq: ONXX) today announced encouraging interim results from a Phase l/II clinical trial of BAY 43-9006 administered in combination with the ... PR Newswire (press release) -
Encouraging Data on BAY 43-9006 in Combination With Standard ... Jun 6, 2004
...(Nasdaq: ONXX - News) today announced encouraging interim results from a Phase l/II clinical trial of BAY 43-9006 administered in combination with the ... Yahoo News (press release) -
Unraveling Biotech Potential Jun 7, 2004
Onyx Pharmaceuticals (Nasdaq: ONXX) is developing a cancer drug called BAY 43-9006 in collaboration with its partner Bayer (NYSE: BAY). ... Motley Fool -
Biotech Market is Sluggish in June Jul 2, 2004
Onyx Pharmaceuticals (ONXX) shares slid 10% after researchers reported that the Onyx-Bayer drug, BAY 43-9006, did not appear to help patients with advanced ... Yahoo News (press release) -
Skin Cancer Pill - - Melanoma Jun 9, 2004
...melanoma. Investigators are studying the oral drug, BAY 43-9006 (a Raf kinase inhibitor) as a potential treatment for melanoma. ... WSOCtv.com, NC -
Wrapping Up the ASCO Conference Jun 7, 2004
As it was before ASCO, it's very difficult to compare the efficacy of Onyx Pharmaceutical's (ONXX:Nasdaq - news - research) BAY 43-9006 and Pfizer's (PFE:NYSE ... TheStreet.com, NY -
Onyx Pharmaceuticals to Webcast June 15 Analyst Briefing Jun 9, 2004
...in Philadelphia, and -- Mark J. Ratain, MD of the University of Chicago, will review recently reported clinical data for BAY 43-9006, being developed in ... PR Newswire (press release) -
New Drugs Offer Hope of Controlling Kidney Cancer Jun 6, 2004
The early-stage studies involved Pfizer Inc.'s experimental pill SU11248, the experimental drug BAY 43-9006 developed by Bayer AG and Onyx Pharmaceuticals Inc. ... Reuters, UK -
Doctors argue over use of placebos in cancer trials Jun 8, 2004
...trials, including OSI Pharmaceuticals, Genentech and Roche Group's Tarceva for lung cancer and Bayer and Onyx Pharmaceuticals Inc.'s BAY 43-9006 for kidney ... MLive.com, MI -
Bayer "neutral" Jun 7, 2004
According to Merrill Lynch’s research note published this morning, Bayer has released data that supports the efficacy of Bay-43 9006 in the treatment of ... New Ratings -
Health Tips Jun 12, 2004
An investigational drug known as BAY 43-9006 (sorafenib) has been shown to benefit some patients with advanced renal cell cancer, researchers say. ... Good Housekeeping Magazine -
Bayer , Onyx : encouraging Phase I / II melanoma trial Jun 6, 2004
CBS.MW) -- Bayer (BAY) and Onyx Pharmaceuticals (ONXX) said it saw encouraging interim results from a Phase l/II clinical trial of BAY 43-9006 melanoma drug. ... CBS MarketWatch -
EUROPE MARKETS Jun 7, 2004
BAY: news, chart, profile), which along with Onyx Pharmaceuticals saw encouraging interim results from a Phase l/II clinical trial of BAY 43-9006 melanoma drug ... CBS MarketWatch -
Genentech, Eli Lilly among firms releasing trial data Jun 5, 2004
...chart, profile) and Onyx Pharmaceuticals (ONXX: news, chart, profile) reported "encouraging" new interim results from a Phase II clinical trial of BAY 43-9006. ... CBS MarketWatch -
Drug results presented on cancer, diabetes Jun 6, 2004
Bayer Pharmaceuticals (BAY) and Onyx Pharmaceuticals (ONXX) reported "encouraging" new interim results from a Phase II clinical trial of BAY 43-9006. ... Investor's Business Daily (subscription) -
Onyx-Bayer drug mix not effective against pancreatic cancer Jun 8, 2004
...said this week. The Onyx-Bayer drug, BAY 43-9006, is being tested for effectiveness in treating several cancers. Studies have shown ... East Bay Business Times, CA -
Bayer, Escada, Heidelberger Druck, Wella: German Equity Preview Jun 7, 2004
...at Germany's second-biggest drug and chemicals maker, is scheduled to speak on a conference call about data on experimental cancer drug BAY 43-9006. ... Bloomberg -
Drugs may make cancer manageable Jun 6, 2004
...hoarse voice. The pill Smith takes, known by the awkward code name BAY 43-9006 , could reach the market in one to three years. It ... Times of India, India -
Annual Cancer Conference Becomes Laboratory for Stocks Jun 7, 2004
A year ago, Onyx stock was trading for about $11. It rose as high as $60 early last month as excitement grew about the drug, called BAY 43-9006. ... New York Times -
Resources from the National Cancer Institute on BAY 43-9006:
Cancer.gov Phase II Randomized Study of BAY 43-9006 in Patients With Refractory Non-Small Cell
Lung Cancer. Date Last Modified: 2004-03-31. Date First Published: 2003-06-23. ...
NSC, Agent Name "723227","(161-180)ESO-1" "726584","(H115D)VHL35" ... 325014","BACTOBOLIN" "649204","BACULOVIRUS CEA PROTEIN VACCINE" "674307","BACULOVIRUS-DERIVED
PSA PROTEIN" "139105","BAF" "724772","BAY 43-9006 tosylate (BAY 54 ...
Molecular Imaging in Ovarian Cancer File Format: PDF/Adobe Acrobat - View as HTML ... VEGF Inhibitors-Bevacizamab • EGFR Inhibitors- Irresa, CI-1033, EMD 72000, OSI-774
(Tarceva), C225 (Irbitux) • Ras-RAF Pathway Inhibitors- Bay 43-9006 ...
The Ideal Target for Cancer Therapy File Format: Microsoft Powerpoint 97 - View as HTML ... eg ZD1839. Antibody to. Receptor. eg Herceptin(R). EGFR antibody. Raf Inhibitor.
eg BAY 43-9006. MEK Inhibitor. eg CI-1040. FTI. eg R115777. CDK Inhibitor. eg Flavopiridol. ...
Cancer.gov - Dictionary BAY 43-9006 A substance that is being studied in the treatment of cancer. It
belongs to the family of drugs called raf kinase inhibitors. BAY 56-3722 ...
NCI-1 DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES ... File Format: PDF/Adobe Acrobat - View as HTMLPage 1. NCI-1 DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES
OF HEALTH National Cancer Institute FY 2005 Budget Page No. ...
|
|
|
